[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338954-105":59,"doc-detail-338954-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","metabolic-adaptation-towards-glycolysis-supports-resistance-to-neoadjuvant-chemotherapy-in-early-triple-negative-breast-cancers","Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers","","Neoadjuvant chemotherapy (NAC) is standard for early-stage triple negative breast cancers, yet over half of patients fail to reach pathological complete response and residual cancer burden predicts poor long-term outcomes. The study investigates mechanisms behind differential treatment responses to limit residual cancer burden and improve NAC efficiency. Using TNBC cell lines and patient-derived organoids with real-time metabolic assays, paclitaxel and epirubicin effects on tumor glycolysis are tested.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/metabolic-adaptation-towards-glycolysis-supports-resistance-to-neoadjuvant-chemotherapy-in-early-triple-negative-breast-cancers/338954/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/metabolic-adaptation-towards-glycolysis-supports-resistance-to-neoadjuvant-chemotherapy-in-early-triple-negative-breast-cancers/338954.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem does the study address in early triple negative breast cancer?","Question",{"text":112,"@type":113},"More than half of patients do not achieve pathological complete response after neoadjuvant chemotherapy, and residual cancer burden is linked to poor long-term prognosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the relationship between NAC and tumor metabolism evaluated?",{"text":117,"@type":113},"The work used TNBC cell lines and patient-derived organoids combined with real-time metabolic assays, focusing on glycolysis, and pre-NAC biopsies analyzed by bulk RNA-sequencing.",{"name":119,"@type":110,"acceptedAnswer":120},"What metabolic change was observed after paclitaxel treatment?",{"text":121,"@type":113},"Paclitaxel induced a metabolic switch to glycolysis and was associated with reduced mitochondrial oxidative metabolism in TNBC cells.",{"name":123,"@type":110,"acceptedAnswer":124},"How does glycolysis inhibition affect treatment response?",{"text":125,"@type":113},"In organoid models from pre-NAC diagnostic material, glycolysis inhibition greatly improved response to NAC, supporting glycolysis-driven resistance as a mechanism.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},338954,1790146925,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Derouane etal. Breast Cancer Research (2024) 26:29  \n[https://doi.org/10.1186/s13058-024-01788-8](https://doi.org/10.1186/s13058-024-01788-8)  \nBreast Cancer Research  \n RESEARCH Open Access  \nMetabolic adaptation towards glycolysis   supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers  \nFrançoise Derouane1,2,3†, Manon Desgres4†, Camilla Moroni4, Jérôme Ambroise5, Martine Berlière3,6,7, Mieke R. Van Bockstal3,8, Christine Galant3,8,9, Cédric van Marcke 1,2,3, Marianela Vara‑Messler4,14,  \nStefan J. Hutten 10,11, Jos Jonkers10,11, Larissa Mourao 12,13, Colinda L. G. J. Scheele 12,13, Francois P. Duhoux 1,2,3 and Cyril Corbet4*  \nAbstract  \nBackground Neoadjuvant chemotherapy (NAC) is the standard of care for patients with early‑stage triple negative breast cancers (TNBC) . However, more than half ofTNBC patients do not achieve a pathological complete response (pCR) after NAC, and residual cancer burden (RCB) is associated with dismal long‑term prognosis. Understand‑ ing the mechanisms underlying differential treatment outcomes is therefore critical to limit RCB and improve NAC efficiency.  \nMethods Human TNBC cell lines and patient‑derived organoids were used in combination with real‑time metabolic assays to evaluate the effect of NAC (paclitaxel and epirubicin) on tumor cell metabolism, in particular glycolysis. Diag‑ nostic biopsies (pre‑NAC) from patients with early TNBC were analyzed by bulk RNA‑sequencing to evaluate the pre‑ dictive value of a glycolysis‑related gene signature.  \nResults Paclitaxel induced a consistent metabolic switch to glycolysis, correlated with a reduced mitochondrial oxidative metabolism, inTNBC cells. In pre‑NAC diagnostic biopsies from TNBC patients, glycolysis was found to be upregulated in non‑responders. Furthermore, glycolysis inhibition greatly improved response to NAC inTNBC orga‑ noid models.  \nConclusions Our study pinpoints a metabolic adaptation to glycolysis as a mechanism driving resistance to NAC inTNBC. Our data pave the way for the use of glycolysis‑related genes as predictive biomarkers for NAC response, as well as the development of inhibitors to overcome this glycolysis‑driven resistance to NAC in human TNBC patients. Keywords Early triple negative breast cancer, Neoadjuvant chemotherapy, Organoids, Metabolism, Glycolysis, Therapy resistance  \n†Françoise Derouane and Manon Desgres have equally contributed to this work.  \n*Correspondence:  \nCyril Corbet  \ncyril.corbet@uclouvain.be  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativecom](http://creativecom)‑ [mons.org/publicdomain/zero/1.0/](mons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nDerouane etal. Breast Cancer Research (2024) 26:29  \nBackground  \nN","cbCaimnIZBTSf7xt","https://ap.wps.com/l/cbCaimnIZBTSf7xt","pdf",10210886,"English","# Background\n## Methods\n## Results\n## Conclusions\n# Keywords","[{\"question\":\"What clinical problem does the study address in early triple negative breast cancer?\",\"answer\":\"More than half of patients do not achieve pathological complete response after neoadjuvant chemotherapy, and residual cancer burden is linked to poor long-term prognosis.\"},{\"question\":\"How was the relationship between NAC and tumor metabolism evaluated?\",\"answer\":\"The work used TNBC cell lines and patient-derived organoids combined with real-time metabolic assays, focusing on glycolysis, and pre-NAC biopsies analyzed by bulk RNA-sequencing.\"},{\"question\":\"What metabolic change was observed after paclitaxel treatment?\",\"answer\":\"Paclitaxel induced a metabolic switch to glycolysis and was associated with reduced mitochondrial oxidative metabolism in TNBC cells.\"},{\"question\":\"How does glycolysis inhibition affect treatment response?\",\"answer\":\"In organoid models from pre-NAC diagnostic material, glycolysis inhibition greatly improved response to NAC, supporting glycolysis-driven resistance as a mechanism.\"}]","Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers | PDF",1790026763,48,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5f57b84956d1bb3bffd34d92882f226.webp",983,1305,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44521ac2106effaf921e8ca56ac53891.webp",982,1304,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb870048508bd89a65cf57005e34d0c8.webp",981,1303,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe82d42aaa78065f082a6ebd9a83e223.webp",980,1301]